Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study

Authors :: De Mel, Sanjay
Goh, Jasmine
Rashid, Masturah
Hoppe, Michal
Zhang, Xi Yun
Jaynes, Patrick
Ng, Esther KY
Rahmat, Nur Atiqa Diana Binte
Liu, Xin
Poon, Michelle
Chan, Hian Li Esther
Lee, Joanne
Chee, Yen-Lin
Koh, Liang Piu
Tan, Lip Kun
Soh, Teck Guan
Yuen, Yi Ching
Loi, Hoi Yin
Ng, Siok Bian
Goh, Xueying
Tan, Daryl
Cheah, Daryl Ming Zhe
Pang, Wan Lu
Huang, Dachuan
Somasundaram, Nagavalli
Tang, Tiffany
Chan, Jason Yongsheng
Lim, Soon Thye
Ong, Choon Kiat
Chng, Wee Joo
Chow, Edward KH
Jeyasekharan, Anand
Source :: Blood; November 2021, Vol. 138 Issue: Supplement 1 p720-720, 1p
Publication Year :: 2021
Abstract: Chng: Amgen: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Novartis: Honoraria; Abbvie: Honoraria.everolimus palbociclib for diffuse large B cell lymphoma and rhomidepsin Bortezomib for extra nodal NK T cell lymphoma

Full Text Access

Tools